Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Non-Current Debt (2024 - 2025)

Eton Pharmaceuticals' Non-Current Debt history spans 2 years, with the latest figure at $27.6 million for Q3 2025.

  • For Q3 2025, Non-Current Debt changed N/A year-over-year to $27.6 million; the TTM value through Sep 2025 reached $27.6 million, changed N/A, while the annual FY2024 figure was $29.8 million, N/A changed from the prior year.
  • Non-Current Debt for Q3 2025 was $27.6 million at Eton Pharmaceuticals, up from $27.4 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $29.8 million in Q4 2024 and bottomed at $27.4 million in Q2 2025.